Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

emergent biosolutions inc. - EBS

EBS

Close Chg Chg %
9.39 0.09 0.91%

Closed Market

9.48

+0.09 (0.91%)

Volume: 799.40K

Last Updated:

Nov 22, 2024, 3:59 PM EDT

Trade Now

Company Overview: emergent biosolutions inc. - EBS

EBS Key Data

Open

$9.39

 Day Range

9.37 - 9.67

52 Week Range

1.42 - 15.09

 Market Cap

$509.33M

Shares Outstanding

54.18M

 Public Float

52.02M

Beta

1.57

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$4.00

Yield

0.00%

 Dividend

$1.86

EX-DIVIDEND DATE

Aug 1, 2016

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.58M

  

EBS Performance

1 Week
 
 22.80%
 
1 Month
 
 6.16%
 
3 Months
 
 -0.52%
 
1 Year
 
 353.59%
 
5 Years
 
 -81.51%
 

EBS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About emergent biosolutions inc. - EBS

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

EBS At a Glance

Emergent BioSolutions, Inc.
300 Professional Drive
Gaithersburg, Maryland 20879
Phone 1-240-631-3200 Revenue 1.05B
Industry Pharmaceuticals: Major Net Income -760,500,000.00
Sector Health Technology Employees 1,600
Fiscal Year-end 12 / 2024
View SEC Filings

EBS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.117
Price to Book Ratio 0.193
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -20.715
Enterprise Value to Sales 0.847
Total Debt to Enterprise Value 0.987

EBS Efficiency

Revenue/Employee 655,812.50
Income Per Employee -475,312.50
Receivables Turnover 5.494
Total Asset Turnover 0.42

EBS Liquidity

Current Ratio 1.043
Quick Ratio 0.538
Cash Ratio 0.172

EBS Profitability

Gross Margin 27.876
Operating Margin -16.392
Pretax Margin -69.685
Net Margin -72.477
Return on Assets -30.413
Return on Equity -74.669
Return on Total Capital -49.81
Return on Invested Capital -51.375

EBS Capital Structure

Total Debt to Total Equity 135.146
Total Debt to Total Capital 57.473
Total Debt to Total Assets 47.823
Long-Term Debt to Equity 70.892
Long-Term Debt to Total Capital 30.148
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Emergent Biosolutions Inc. - EBS

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
1.56B 1.79B 1.12B 1.05B
Sales Growth
+40.63% +15.26% -37.66% -6.10%
Cost of Goods Sold (COGS) incl D&A
552.10M 813.10M 750.40M 756.80M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
114.40M 126.30M 148.90M 129.10M
Depreciation
54.60M 67.80M 89.00M 63.50M
Amortization of Intangibles
59.80M 58.50M 59.90M 65.60M
COGS Growth
+18.12% +47.27% -7.71% +0.85%
Gross Income
1.00B 979.60M 367.10M 292.50M
Gross Income Growth
+57.11% -2.36% -62.53% -20.32%
Gross Profit Margin
+64.50% +54.64% +32.85% +27.88%
2020 2021 2022 2023 5-year trend
SG&A Expense
508.80M 581.50M 526.00M 464.50M
Research & Development
205.50M 234.00M 188.30M 107.80M
Other SG&A
303.30M 347.50M 337.70M 356.70M
SGA Growth
+1.82% +14.29% -9.54% -11.69%
Other Operating Expense
- - - -
-
Unusual Expense
64.60M 45.50M 11.10M 554.40M
EBIT after Unusual Expense
429.90M 352.60M (170.00M) (726.40M)
Non Operating Income/Expense
4.70M (9.50M) (11.80M) 92.00M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
27.40M 28.70M 37.20M 96.80M
Interest Expense Growth
-29.74% +4.74% +29.62% +160.22%
Gross Interest Expense
27.40M 28.70M 37.20M 96.80M
Interest Capitalized
- - - -
-
Pretax Income
407.20M 314.40M (219.00M) (731.20M)
Pretax Income Growth
+426.10% -22.79% -169.66% -233.88%
Pretax Margin
+26.18% +17.54% -19.60% -69.68%
Income Tax
102.10M 83.50M (7.40M) 29.30M
Income Tax - Current - Domestic
90.50M 11.20M (7.50M) (100.00K)
Income Tax - Current - Foreign
14.00M 28.40M 33.80M 36.70M
Income Tax - Deferred - Domestic
1.10M 42.30M (40.90M) (3.20M)
Income Tax - Deferred - Foreign
(3.50M) 1.60M 7.20M (4.10M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
305.10M 230.90M (211.60M) (760.50M)
Minority Interest Expense
- - - -
-
Net Income
305.10M 230.90M (211.60M) (760.50M)
Net Income Growth
+459.82% -24.32% -191.64% -259.40%
Net Margin Growth
+19.62% +12.88% -18.94% -72.48%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
305.10M 230.90M (211.60M) (760.50M)
Preferred Dividends
- - - -
-
Net Income Available to Common
305.10M 230.90M (211.60M) (760.50M)
EPS (Basic)
5.7894 4.3159 -4.2236 -14.8535
EPS (Basic) Growth
+447.10% -25.45% -197.86% -251.68%
Basic Shares Outstanding
52.70M 53.50M 50.10M 51.20M
EPS (Diluted)
5.671 4.268 -4.2236 -14.8535
EPS (Diluted) Growth
+445.24% -24.74% -198.96% -251.68%
Diluted Shares Outstanding
53.80M 54.10M 50.10M 51.20M
EBITDA
608.90M 524.40M (10.00M) (42.90M)
EBITDA Growth
+143.76% -13.88% -101.91% -329.00%
EBITDA Margin
+39.15% +29.25% -0.89% -4.09%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 12.00
Number of Ratings 3 Current Quarters Estimate -0.41
FY Report Date 12 / 2024 Current Year's Estimate -1.06
Last Quarter’s Earnings 1.37 Median PE on CY Estimate N/A
Year Ago Earnings -6.23 Next Fiscal Year Estimate 1.745
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 1 3 2
Mean Estimate -0.41 1.50 -1.06 1.75
High Estimates -0.07 1.50 -0.88 2.99
Low Estimate -0.64 1.50 -1.30 0.50
Coefficient of Variance -73.29 N/A -20.41 100.90

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 1 1 0
MEAN Overweight Overweight Buy

Insider Actions for Emergent Biosolutions Inc. - EBS

Date Name Shares Transaction Value
Jul 11, 2024 Paul Anthony Williams SVP, Products Business 24,333 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.13 per share 197,827.29
Jun 12, 2024 Coleen Glessner EVP, Quality & Ethics, and CPL 163,134 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $6.19 per share 1,009,799.46
Jun 12, 2024 Jennifer L. Fox EVP, Ext Aff, GC, Corp Sec 171,382 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $6.19 per share 1,060,854.58
Jun 12, 2024 William Hartzel SVP, Bioservices 33,107 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $6.19 per share 204,932.33
Jun 12, 2024 Richard Scott Lindahl EVP, Chief Financial Officer 156,009 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $6.19 per share 965,695.71
Jun 7, 2024 Kathryn C. Zoon Director 54,482 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.11 per share 332,885.02
May 29, 2024 Zsolt Pál Harsányi Chairman; Director 25,748 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Keith A. Katkin Director 59,872 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Donald W. DeGolyer Director 136,100 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Sujata Tyagi Dayal Director 25,748 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Sujata Tyagi Dayal Director 63,129 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Neal F. Fowler Director 25,748 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Neal F. Fowler Director 136,100 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Marvin L. White Director 68,379 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Zsolt Pál Harsányi Chairman; Director 89,329 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Keith A. Katkin Director 25,748 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Ronald B. Richard Director 25,748 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Ronald B. Richard Director 71,114 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Louis Wade Sullivan Director 25,748 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 29, 2024 Louis Wade Sullivan Director 104,695 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Emergent Biosolutions Inc. in the News